In this issue:
Trastuzumab deruxtecan in HER2-low metastatic breast cancer
First-line ribociclib 600 vs. 400mg in hormone receptor+, HER2– advanced breast cancer
Adjuvant carboplatin-intensified chemotherapy in high-risk, early-stage, triple-negative breast cancer
Outcomes of anastrozole, letrozole and exemestane in postmenopausal breast cancer
Adjuvant chemotherapy for hormone receptor+, HER2– breast cancer
Fear and medical misinformation in breast cancer
Pembrolizumab extended-interval dosing in breast cancer
First-line ribociclib + letrozole in elderly hormone receptor+, HER2– advanced breast cancer
Predicting heart failure and cardiomyopathy after breast cancer treatment
ARX788 for HER2+ breast cancer and brain metastases
Please login below to download this issue (PDF)